Billionaire Herriot Tabuteau's Axsome wins FDA acceptance for narcolepsy drug

The U.S. Food and Drug Administration has accepted for review a new narcolepsy drug from Axsome Therapeutics, the biotech built by Haitian-born billionaire Herriot Tabuteau, advancing a treatment that forms part of his plan to file a new medicine every year through 2030.

Axsome said on Tuesday that the agency accepted its new drug application for AXS-12, a treatment for cataplexy in narcolepsy, and set a decision date of May 1, 2027. The FDA indicated it does not currently plan to convene an advisory committee to review the application, a signal that regulators see no need for outside scrutiny before ruling.

Cataplexy is a sudden loss of muscle tone triggered by strong emotion, one of the most disabling symptoms of narcolepsy. AXS-12, known chemically as reboxetine, is designed to maintain muscle tone during wakefulness and to support alertness and cognition. The FDA has granted it orphan drug designation, a status for treatments of rare conditions that can carry seven years of market exclusivity on approval.

The acceptance matters more for what it represents than for its immediate financial weight. Tabuteau has set a deliberately aggressive schedule, aiming to file at least one new drug application each year from 2026 through 2030, and AXS-12 is among the filings meant to prove that pace is achievable. He has said Axsome's full pipeline could eventually generate more than $20 billion in peak annual sales.

The company is moving from promise to revenue at speed. Axsome booked $709 million in sales over the 12 months through the first quarter, up 64% from a year earlier. William Blair analyst Myles Minter has projected sales of $975 million this year and $1.7 billion in 2027, citing a pipeline that gives the company what he called multiple shots on goal, including the narcolepsy and fibromyalgia programs.

That growth has transformed Tabuteau's fortune. Shares of Axsome doubled over nine months, lifting his net worth to $2.2 billion, from a company worth $6.1 billion last October to a market value that has since climbed past $12.6 billion. He owns about 15% of the business, plus options, and Forbes ranks him at number 2,600 on its 2026 billionaires list. He was the first person born in Haiti to appear on the ranking.

The surge has been driven mainly by Auvelity, Axsome's treatment for agitation in Alzheimer's disease, which won FDA approval weeks ago and reached the market as the first non-antipsychotic cleared for the condition. More than 7 million Americans live with Alzheimer's, and Axsome estimates up to 76% of them experience agitation, a market doctors have long managed with antipsychotics that carry serious risks.

Tabuteau built the company against the grain of his industry. He founded Axsome in 2012 with a focus on brain disorders, a field most large drugmakers had been exiting because the science was hard and the failure rates high. He took no venture capital, self-funding with help from friends and family, and ran clinical trials in-house to cut costs by up to half. He serves as both chief executive and scientific founder, and is listed as an inventor on more than 200 patents.

His path to biotech ran through Wall Street. Born in Haiti, where he has said he experienced neglect before moving to Manhattan's Upper East Side at age nine with his father and adoptive mother, he trained at Wesleyan and Yale School of Medicine, then spent nearly two decades in healthcare finance. He worked at Goldman Sachs and Banc of America Securities before becoming a partner at the hedge fund operation tied to S.A.C. Capital, running its biotechnology portfolios. That vantage point, watching thousands of early-stage biotechs succeed and fail, shaped the portfolio strategy he later built Axsome around.

The narcolepsy filing fits the model of spreading risk across many programs rather than betting on one. Axsome has three approved drugs on the market and several more in late-stage development, targeting depression, migraine, Alzheimer's agitation and other conditions that affect an estimated 150 million Americans. Tabuteau has framed the current run as an early chapter, arguing the company is small in size but not in ambition.

AXS-12 still must clear the FDA's review, and approval is not assured. The May 2027 decision date leaves nearly a year of scrutiny ahead, and the drug would then have to win market share in a narcolepsy field that includes established treatments. The absence of a planned advisory committee meeting removes one hurdle, but the agency retains full discretion over the final ruling.

For Tabuteau, the filing keeps a self-imposed clock running. He has staked Axsome's next phase on a cadence of annual submissions, and each acceptance is a marker that the strategy is holding. The narcolepsy drug is now on the calendar, with a date attached and the outcome still to be decided.